Seeking Alpha

Sam Subramanian's  Instablog

Sam Subramanian is editor and publisher of the highly acclaimed AlphaProfit Sector Investors’ Newsletter. The Newsletter has been ranked #1 several times by Hulbert Financial and has featured among MartketWatch’s top 10 investment newsletters. Sam is well known for his sector analysis... More
My business:
AlphaProfit Investments, LLC
My blog:
AlphaProfit MoneyMatters
  • Deals return to the biotech space 0 comments
    Sep 4, 2009 09:14 PM | about stocks: DNPUF.PK, BIIB, SEPR, FACT, TRBN
    On July 27, I had commented on deals being one of the factors driving stock prices in the biotech group. The spate of deals continues.

    Earlier this week, Sepracor (SEPR) agreed to be bought by Japan's Dainippon Sumitomo Pharma (
    DNPUF.PK) for $2.6 billion. This purchase will enable Dainippon to gain a U. S. sales force along with experimental treatments for asthma, allergic rhinitis, and insomnia.

    Today, Biogen Idec (BIIB) made an unsolicited $356 million cash takeover offer for drug partner Facet Biotech (FACT). The $14.50 a share offer represents a 64% premium to Facet's share price. Earlier Facet rejected a higher offer from Biogen to collaborate with Trubion Pharmaceuticals (TRBN).

     
Back To Sam Subramanian's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Full index of posts »
Posts by Ticker

Latest Comments


Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.